Interactions between human recombinant H-and L-ferritins and human lymphocytes were studied in vitro by direct binding assays and by flow cytometry. L-ferritin did not cause detectable specific binding, whereas H-ferritin showed a specific and saturable binding that increased markedly in phytohemagglutinin (PHA)-stimulated cells. This ferritin bound up to 30% of CD4+ and CD8t T-lymphocytes and most B cells, indicating that expression of ferritin binding sites is not related to cell lineage or function. Dual-color flow cytometry experiments showed that ferritin binding sites were present on cells expressing the proliferation markers ERRITIN, AN IRON-BINDING protein present in F almost all living cells, is composed of 24 subunits of two types, known as H and L, which assemble in different proportions in the various tissues.'" The major function of ferritin is to store intracellular iron. The two subunits appear to have specialized roles: H-ferritin has a ferroxidase activity and is involved in rapid iron uptake and iron detoxification, whereas the more stable L-ferritin is involved in long-term iron storage?' Other functions unrelated to iron storage have been attributed to ferritin: the first function, suggested by Mazur and Shorr in 1950, was a vasosuppressor activity.' More recent studies examined the interactions between ferritin and myeloid progenitor cells or lymphocytes; they showed that ferritin has an inhibitory activity in vitro and in vivo on proliferation of the precursors of GM and erythrocyte lineages?.'' Production of homogeneous recombinant human H-and L-ferritins (rHF and rLFo) allowed inhibitory activity to be detected on the H-subunit:" and study of various H-ferritin mutants showed that this activity is closely linked to H-chain ferroxidase activity, which may interfere with cellular iron uptake.13 The effects of ferritin on lymphocytes are less clear. Early reports indicated that ferritin is present on the surface of a subpopulation of lymphocytes and that it causes inhibition of T-lymphocyte E rosette f~rmation.~~-~' Removal of surface ferritin by incubation in levamisole or fetal calf serum (FCS) resulted in restoration of E rosette formation.18.20 In addition, the subpopulation of circulating lymphocytes carrying surface ferritin expanded in tumor and 
HLA-DR, MLRB, interleukin 2 (lL-2), and transferrin receptors (Tf-R). In addition, after
membrane ferritin was mainly recognized by anti-Hferritin antib0dies.2~ The origin and significance of lymphocyte-bound ferritin remained unclear.
Membrane binding sites specific for H-ferritin (Ft-BS) have been identified in various cell lines such as K562 and HL60,26-= and on erythroid progenitor cells,29 and their expression was shown to be modulated by cellular proliferation and differentiation?"" The existence of such binding sites on lymphocytes might explain both the presence of membrane ferritin and the inhibitory activity of ferritin on in vitro lymphocyte proliferation and migrati~n.~~""~"
We investigated in vitro binding of rHF and rLFo to lymphocytes in different states of growth and the effects of such ferritins on lymphocyte proliferation. Our results show the presence of specific H-ferritin binding sites on proliferating lymphocytes, which are probably involved in the H-ferritin suppressive activity.
MATERIALS AND METHODS
Lymphocytes were isolated from peripheral blood (PB) of normal human donors by Ficoll-Hypaque gradient centrifgati ion.^* Cells (5 x 10') were cultured for 72 hours in 0.6 mL RPMI 1640 (Flow Laboratories, Imine, Scotland, UK) with addition of 10% FCS (Flow) with or without 10 pg (GIBCO, Grand Island, NY).
Ferritins. rHF and rLFo were over expressed in Escherichia coli, extracted, and purified as previously de~cribed.'~~~" L-Ferritin carries a substitution of the first two amino acids Ser-Ser by Asp-Pro6 and is therefore named rLFo. Both proteins were pure by electrophoresis analyses.
Iodination of fem'tins. Ferritins were freshly iodinated before each experiment, as described by Fraker and S p e~k . '~ Forty micrograms purified rHF and rLFo was added to 1 mCi lZI sodium iodine (Amersham, England) with 10 kg 1 mgimL 1,3,4,6-tetrachloro-3a, 6a-diphenylglycouril (Iodo-gen, Sigma, St Louis, MO), and incubated for 20 minutes at 37°C. Bound radioactivity was separated by gel filtration on Sephadex G25 (Pharmacia, Uppsala, Sweden). The specific radioactivity was 7,000 to 15,000 cpming for rHF and 2,500 to 5,000 cpmlng for rLFo, 95% to 98% precipitable by 10% trichloroacetic acid (TCA).
Ferritin cell binding was performed as already described." Lymphocytes 2 x 10' in 50 pL 10% fetal calf serum (FCS) RPMI 1640 were incubated for 60 minutes at 37°C with saturating concentrations of radioiodinated rHF or rLFo in 50 pL phosphate-buffered saline (PBS) containing 1 mgimL bovine serum albumin (BSA). Cells were washed three times in saline, and the bound radioactivity was counted. Nonspecific binding was
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determined by addition of a 3l)cl-fold excess of unlabeled ferritins and subtracted from the total binding.
Lymphocytes, 5 X lo5 cells, were cultured as above for 72 hours in 0.6 mL, with or without addition of 10 Fg PHA with various concentrations of ferritin. Methyl 3H-thymidine (2 PCi) (Amersham) was added 4 hours before the end of the culture. Cells were harvested, and thymidine incorporation was assessed. The results were expressed as PHA index.3D
To label the ferritin binding sites we used the following procedure: lo6 lymphocytes suspended in 0.1 mL were incubated with 10 pL purified rHF or rLFo at 1 mg/mL for 30 minutes at 4"C, washed three times in 3 mLPBS supplemented with 0.1% sodium azide and 2% inactivated FCS pH 7.2, incubated for 40 minutes with 50 pL 0.5 mg/mL monoclonal antibodies (MoAbs) 2A4 and LF03 specific for the Hand L-ferritins, respe~tively,"~,~ washed again, and incubated with 8 JLL FITC-labeled goat anti-mouse immunoglobulin (GAM-Ig) antibody (Becton Dickinson, Mountain View, CA) for 25 minutes at 4°C. Cells were washed again and analyzed by flow ~y t o m e t r y .~~ Controls consisted of cells treated as above but without incubation with the antiferritin antibodies, which were replaced by a nonspecific mouse MoAb of the same isotype as the antiferritin antibody.
The washed cells (50 pL), labeled as described above, were further incubated with 10 JLL unrelated MoAb for 15 minutes at 4°C to saturate free residual binding sites. After the cells were washed, they were incubated with 25 PLphycoerythrin (PE)-conjugated MoAb for CD4 (Leu3a), CD8 (Leu2a), CD19 (Leul2), HLA-DR, MLR3 (CD69), IL-2-R (CD25), and Tf-R (CD71) (Becton Dickinson) for 20 minutes at 4°C. The cells were washed twice before flow cytometry analysis.
Cell viability was estimated by addition of 50 FL 5 Fg/mL ethidium bromide (Sigma) to 50 pL cell suspensions and analysis by flow c y t~m e t r y ?~.~~ Only samples with viability greater than 90% were taken into consideration. Cell membranes were made permeable by incubation in ice-cold 70% ethanol in PBS for 10 minutes, and DNA was then stained by incubation in 1 pg/mL propidium iodine (Sigma) for at least 3 hours in the dark. The cell cycle was calculated by analyzing the DNA of 50,000 cells in flow cytometry and computing the results with a sum of broadened rectangle algorithm (Becton Dickinson); the cycle phases were expressed as percentage value^.'^ DNA staining was performed on 0.2 to 0.5 mL cells previously labeled for surface ferritin as described above. The permeabilization procedure in 70% ethanol did not affect surface staining significantly.
A standard four-parameter flow cytometer, equipped with a 2-W argon-ion laser (FACS, Becton Dickinson) was used. For single-and dual-color surface analysis, the cells were gated with a forward v side scatter cytogram to exclude dead cells or aggregates. For dual-color analyses, an appropriate compensation network was set for FITCiPE combination. A fonvardlside scatter cytogram was also used to select cells for viability analysis. At least 10,000 cells were analyzed in every run. Fluorescence was detected in log amplification mode, and the results were expressed either as monoparametric histograms or as bivariate cytograms or contour plots. Negative control samples were used to set appropriate positive windows, and the background count in the control was always subtracted from the positive cell samples. For single-and dual-color DNA analysis, cells were selected on the basis of red (DNA) fluorescence with an appropriate threshold and trigger.
Cells cultured in 10% FCS RPMI 1640 with or without PHA were harvested after lo-, 34-, 60-, and 84-hour culture. At each time, dual-color analysis was performed as described by Brando et al.3R
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RESULTS
H-and L-ferritin binding sites. Radiolabeled recombinant H-and L-ferritins were incubated with lymphocytes either untreated or incubated with or without PHA. L-ferritin binding was never detectable; in contrast, H-ferritin showed a significant binding to cultured lymphocytes, which increased more than threefold in the PHA-stimulated cells. Fresh, uncultured cells did not bind detectable ferritin (Table 1) . Saturation experiments with increasing concentrations of lZ5I-rHF detected about 12,000 rHF binding sites in the PHA-activated cells, with an apparent ka of 1.4 X 10' mo1L-I (data not shown). Parallel experiments with immunofluorescence flow cytometry detected a specific binding of L-ferritin to 2% of the cells or less, whereas H-ferritin bound 4% and 27% of the PHA-unstimulated and PHAstimulated cells, respectively (Table 1) .
Further flow cytometry experiments, aimed at assessing whether the low binding of L-ferritin was significant, showed background bindings of 3% to 5% positive cells with antiferritin antibodies alone or with mismatched antibodies and that rLFo (and its antibody) was not incremental to the fluorescence associated with rHF and its antibody (ranges of three experiments: 23% to 27.8% and 23.7% to 28.4%, respectively). Thus, the present approach does not demonstrate specific binding sites for the L-ferritin on lymphocytes. Further binding studies were performed with H-ferritin.
PHAstimulated cells were labeled for rHF binding with green FITC antibodies and for other lymphocyte markers with PE-conjugated antibodies. Dual-color flow cytometry results are shown in Fig 1 and summarized in Table 2 . H-Ft-BS were found on all CD19+ B cells, on about 30% of CD4+ T-helper cells, and on 30% of CD8+ T-suppressor subsets ( Fig 1A) . All H-Ft-BS+ cells expressed the HLA-DR, MLR3, and Tf-R antigens, and a major proportion of H-Ft-BS+ cells (67%) were IL-2-R+. H-Ft-BS and Tf-R (ie, the two iron-binding protein receptors) were proportionately expressed, which was not so evident with the other activation markers (Fig 1B) .
We used flow cytometry to analyze the time course of the expression of H-Ft-BS and the other activation markers during PHA stimulation (Fig 2) . All the markers tended to increase in a parallel fashion and reached a maximum after 60-hour incubation, as previously reported?* Similarly, H-fenitin binding in relation to lymphocyte markers. cent rHF labeling (Fig 3B and C, respectively) indicate that H-ferritin binds cells throughout all the cell cycle including the early S-phase.
Various concentrations of H-and L-ferritins were added to lymphocytes grown for 72 hours with or without PHA, and their proliferation was analyzed by 3H-thymidine incorporation. Neither ferritin had an effect on the unstimulated cells in the concentration range of to lo-* mol/L (not shown), whereas in the presence of PHA H-ferritin reduced the PHA index to about 50% and L-ferritin essentially had no effect (Fig 4) . Addition of anti-H-ferritin MoAb removed the ferritin inhibition.
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DISCUSSION
We and other investigators previously demonstrated the existence of binding sites specific for H-ferritin (or H-rich ferritin) on various human cell these binding sites also exist on normal human lymphocytes, where they have the same affinity constant and can reach a density of 20,000 sites per cell, similar to that of proliferating K562 cells.26 In addition, in lymphocytes, as in K562 cells, H-Ft-BS expression as well was modulated by cellular proliferation and was higher in the PHA-stimulated cells (Table 1) .
We were unable to detect specific L-ferritin binding even in cells showing high binding of H-ferritin, which suggests that L-ferritin binding sites either do not exist on lymphocytes or are so different from H-Ft-BS that they are undetectable with the present method. The lack of rHF binding by fresh lymphocytes poses another problem because the binding sites may be either absent or masked. We favor the latter hypothesis because H-Ft-BS appeared after incubation in FCS medium, a treatment previously shown to shed ferritin from the lymphocyte surface,@ and ferritin is present in the circulation where it may interact with the lymphocyte binding sites. Indeed, the proportion of circulating lymphocytes with membrane-bound ferritin (2% to 5%) detected in various laboratorieszl-x agrees well with the proportion that expressed H-Ft-BS after incubation in FCS (3% to 5%) in this study. Thus, even though an effect of incubation on H-Ft-BS expression cannot be ruled out, in the circulating cells H-Ft-BS probably is occupied by natural ferritin.
In PHA-stimulated lymphocytes, 30% of CD4 T-helper cells, 30% of CD8 T-cytotoxic suppressors, and most CD19 B lymphocytes expressed H-Ft-BS (Table 2 ) (the number of B cells analyzed was too small to establish that H-Ft-BS is a marker for all B lymphocytes). Thus, the distribution of the binding sites among lymphocytes is not related to cellular lineages, a result in keeping with previous data showing that H-Ft-BS exist on cells of varying origin, including liver, lung, and bone marrow.% " Although not related to cellular functional activities, H-Ft-BS expression appears to be closely and positively linked to the proliferative status of the lymphocytes for the following reasons: (a) total rHF binding, as well as the number of cells binding rHF, markedly increased after PHA-induced blastogenesis; (b) almost all cells expressing H-Ft-BS also expressed the activation markers IL-2-R, HLA-DR, MLR3, and Tf-R; (c) during PHA induction, the kinetics of H-Ft-BS expression was roughly parallel to that of the four activation markers; (d) H-Ft-BS exist on cells in various cell cycle phases, including actively proliferating cells in early S-phase." These data are in accord with previous findings showing that H-Ft-BS do not exist in quiescent confluent K562 cells and increase markedly during cell proliferation.26 In addition, H-Ft-BS expression shows a marked similarity to the behavior of CD30, a cluster of antigens of unknown function, accepted as a proliferation marker, which is expressed on K562 and HL60 cells and on about 20% of PHA-stimulated lymphoc y t e~,~' its molecular weight is similar to that previously detected for H-Ft-BS.26 Thus, we suggest that H-Ft-BS could be considered a proliferation marker. The present study with ferritin H-and L-homopolymers confirms previous findings obtained with natural ferritins
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From FARGION ET AL ,DNA c o n t e n t with different proportions of H:L16-*': ferritin has an inhibitory activity on lymphocyte blastogenesis that is associated with the H-chain, whereas the L-chain is noneffective. This ferritin activity on lymphocytes has analogies with the activity exerted on myeloid precursors; in both cases, the suppression is partial and is linked to the presence of the H-chain, and both cell types express H-Ft-BS. A recent study of BFU-E and CFU-GM showed that ferritin suppression results from ferroxidase activity of the H-chain because it disappears in the mutants with this activity deleted, and suppression is reversed by iron supplementation to cells in the form of hemin." Ferroxidase activity has been suggested to interfere with cellular proliferation by inducing iron starvation. A linkage between H-Ft-BS expression and iron metabolism is further suggested by the proportional expression of transferrin and ferritin receptors.
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